Is there any risk of developing antibodies to AOD-9604
TSH is not a required safety test for every GLP-1 user, but it is reasonable when weight change, fatigue, palpitations, constipation, hair shedding or menstrual changes do not fit the expected medication course
Liver mass, on the other hand, was strongly reduced in all groups and correlated tightly with body weight change (r = 0.71), while muscle mass in the uncasted leg was a remarkably poor predictor of body weight (r = 0.09)
May 2021;15(3):676-683
If your regimen includes additional peptides alongside your GLP-1, a general peptide journal may serve you better than one designed specifically for semaglutide or tirzepatide users
Store at -20C desiccated, protected from light, moisture, and oxygen